[ad_1]
ROCKVILLE, Md., Feb. 2, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX) is a company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based cancer therapies. biopharmaceutical company, today announced that its management will participate in the following upcoming investor meetings:
-
Guggenheim Healthcare Lecture | 6th Annual Biotechnology Conference (New York). MacroGenics President and CEO Scott Koenig, MD, PhD, will participate in a fireside chat on Wednesday, February 7, 2024 at 2:00 pm ET. MacroGenics management will also participate in one-on-one meetings.
A webcast of the above presentation can be accessed on the MacroGenics website at http://ir.macrogenics.com/events.cfm under “Events and Presentations” in the Investor Relations section. The company will maintain an archived replay of the webcast on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative cancer therapies based on monoclonal antibodies. The company generates its pipeline of product candidates primarily through its proprietary suite of next-generation antibody-based technology platforms, which are applicable to a broad range of therapeutic areas. The combination of MacroGenics’ technology platform and protein engineering expertise enables the company to develop promising product candidates and enter into multiple strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please visit the company’s website: www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
CONTACT: CONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172, info@macrogenics.com
[ad_2]
Source link